Microbot Medical (NASDAQ:MBOT – Get Free Report) and Sensus Healthcare (NASDAQ:SRTS – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings.
Volatility and Risk
Microbot Medical has a beta of 1.68, indicating that its share price is 68% more volatile than the S&P 500. Comparatively, Sensus Healthcare has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.
Profitability
This table compares Microbot Medical and Sensus Healthcare’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Microbot Medical | N/A | -149.24% | -115.69% |
| Sensus Healthcare | 14.70% | 9.76% | 8.72% |
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Microbot Medical | N/A | N/A | -$10.74 million | ($0.89) | -1.08 |
| Sensus Healthcare | $24.41 million | 4.29 | $490,000.00 | $0.29 | 22.04 |
Sensus Healthcare has higher revenue and earnings than Microbot Medical. Microbot Medical is trading at a lower price-to-earnings ratio than Sensus Healthcare, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
16.3% of Microbot Medical shares are held by institutional investors. Comparatively, 25.3% of Sensus Healthcare shares are held by institutional investors. 10.6% of Microbot Medical shares are held by insiders. Comparatively, 11.1% of Sensus Healthcare shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Analyst Recommendations
This is a breakdown of recent recommendations for Microbot Medical and Sensus Healthcare, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Microbot Medical | 0 | 0 | 1 | 0 | 3.00 |
| Sensus Healthcare | 0 | 0 | 2 | 1 | 3.33 |
Microbot Medical currently has a consensus price target of $7.00, indicating a potential upside of 629.13%. Sensus Healthcare has a consensus price target of $10.00, indicating a potential upside of 56.49%. Given Microbot Medical’s higher probable upside, equities analysts plainly believe Microbot Medical is more favorable than Sensus Healthcare.
Summary
Sensus Healthcare beats Microbot Medical on 12 of the 14 factors compared between the two stocks.
About Microbot Medical
Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.
About Sensus Healthcare
Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sentinel service program, which offers its customers protection for their systems; and Transdermal Infusion system, a biophysical alternative to infuse high weight molecule modalities into the dermis for medical and aesthetic purposes without the use of needles. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Further, the company distributes laser devices, which includes applications for hair removal, vascular lesions, acne treatment, skin toning, and skin rejuvenation, as well as epidermal pigment removal for spots, freckles, and tattoos. It markets its products primarily to private dermatology practices, and radiation oncologists in both private and hospital settings. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.
Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with MarketBeat.com's FREE daily email newsletter.
